⌘K

Login Start Free

Home/Filings/4/0000943819-25-000025

4//SEC Filing

Sandercock Brett 4

Accession 0000943819-25-000025

CIK 0000943819other

View on SEC.gov Company Profile

Filed

Jul 1, 8:00 PM ET

Accepted

Jul 2, 5:53 PM ET

Size

11.9 KB

Accession

0000943819-25-000025

Insider Transaction Report

Form 4

Period: 2025-07-01

Sandercock Brett

Chief Financial Officer

Transactions

Sale
ResMed Common Stock
2025-07-01$256.99/sh−3,883$997,892→ 84,283 total
Exercise/Conversion
ResMed Common Stock
2025-07-01$101.64/sh+917$93,204→ 88,166 total
Exercise/Conversion
ResMed Common Stock Options
2025-07-01−1,966→ 8,917 total
Exercise: $101.64From: 2019-11-11Exp: 2025-11-14→ ResMed Common Stock (1,966 underlying)
Exercise/Conversion
ResMed Common Stock Options
2025-07-01−917→ 8,000 total
Exercise: $101.64From: 2019-11-11Exp: 2025-11-14→ ResMed Common Stock (917 underlying)
Exercise/Conversion
ResMed Common Stock
2025-07-01$101.64/sh+1,966$199,824→ 87,249 total

Footnotes (2)

[F1]The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.
[F2]Represents date options first become exercisable. Options vest 1/3 per year.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

RESMED INC

CIK 0000943819

Entity typeother

Related Parties

1

filerCIK 0001346064

Filing Metadata

Form type: 4
Filed: Jul 1, 8:00 PM ET
Accepted: Jul 2, 5:53 PM ET
Size: 11.9 KB

View on SEC.gov